Zhejiang Hisun Pharma will raise at least 2 billion RMB ($328 million) in a private placement. The company will offer up to 139.5 million new shares at a price not lower than 14.26 RMB per share (current price is 17.22 RMB). Hisun will use the money to build facilities for three projects: facilities for solid preparations and injections, solid preparation cancer treatments and the Phase II of its biopharmaceutical initiative.
Celsion website; Company news;
September 9, 2013
Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials to be Presented at the 2013 San Antonio Breast Cancer Conference
P4-15-05 Novel targeted therapy for breast cancer chest wall recurrence: Low temperature liposomal doxorubicin and mild local hyperthermia
Rugo HS, Zagar TM, Formenti SC, Vujaskovic Z, Muggia F, O'Connor BM, Myerson RJ, Hsu IC-C, Borys N, Blackwell KL, Dewhirst MW. University of California San Francisco Medical Center, San Francisco, CA; University of North Carolina Hospital, Chapel Hill, NC; New York University Medical Center, New York, NY; University of Maryland Medical Center, Baltimore, MD; Commonwealth Hematology/Oncology PC, Plymouth, MA; Washington University in St. Louis Medical Center, St. Louis, MO; Celsion Corporation, Lawrenceville, NJ; Duke University Medical Center, Durham, NC.
Japanese approval of Zerenex--which is a virtual certainty. Price came down $2.00 and it is going back up to between $16-$18/share. Japanese approval is expected within the next few days to weeks. CEO speaking at Oppenheimer conference Wednesday. Great opportunity for a 20-40% return in a very short time. KERX saved my #$%$ following the crash of CLSN back in Jan. CLSN not going anywhere for quite a while but KERX will move back up to $16-$18 ino and following approval. You're welcome. Oh---and I forst found out about KERX right here as an investor in CLSN too.
Sentiment: Strong Buy
Merrimack Pharmaceuticals to Present Phase 1 Data on MM-302 in Patients With Advanced HER2-Positive Breast Cancer
Expanded Phase 1 Study Results on Safety and Dosage Levels of MM-302 to be Presented at the 2013 San Antonio Breast Cancer Symposium.
5 hours ago
...Content preferences ....Done ..
....CAMBRIDGE, Mass., Dec. 6, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (MACK) today announced that Phase 1 data evaluating safety of the novel agent MM-302 in patients with advanced HER2-positive breast cancer will be presented at the 2013 San Antonio Breast Cancer Symposium (SABCS), December 10-14, 2013 in San Antonio, Texas.
MM-302, an antibody drug conjugated liposomal doxorubicin, specifically targets cancer cells that overexpress the HER2/ErbB2 receptor. This targeted liposomal encapsulation of doxorubicin is designed to allow for the selective uptake of drug into tumor cells while limiting exposure to healthy tissues, such as those of the heart.
The Phase 1 trial for MM-302 enrolled patients with advanced HER2-positive breast cancer who have progressed or recurred on standard therapy. Data to be presented will include safety results for all treated patients in the trial, as well as preliminary activity in patients treated with therapeutically relevant dose levels of MM-302 alone and in combination with trastuzumab.
In addition, results will be presented from a research collaboration with the laboratory of Peter Sorger, Ph.D., from Harvard Medical School. In this collaboration, statistical models were used to generate preclinical response biomarker hypotheses for targeted inhibitors.
I'd be happy with $10 by the end of NEXT year. :-)
I think CLSN will trade sideways for a while. i'm not selling in the near future, but I've invested all I'm going to (for now)
Nothing will happen with the share price, one way or another, until there are some definitive results from one of the trials. Why would it change at all without news? We’re back to square one, so let’s hope they get it right this [one last] time